Investor Relations Contact:
ir@anacor.com
Phone: 650-543-7575
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.
May 10, 2012
Anacor Pharmaceuticals Reports First Quarter 2012 Financial Results
May 4, 2012
Anacor Pharmaceuticals to Present Clinical Data on Tavaborole and AN2728 at Upcoming Medical Meetings
View all »Events & Presentations
May 10, 2012 at 2:00 PM PT
Anacor First Quarter 2012 Financial Results Conference Call
May 7, 2012 at 4:10 PM ET
Deutsche Bank Annual Health Care Conference
Receive Email Alerts
Sign up to receive e-mail alerts whenever Anacor posts new information to the site.
